Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 45175G108 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
Orbimed Advisors LLC
13D/A
|
13.1% |
4/29/2026
Event 4/14/2026
|
||
| Orbimed Advisors LLC | 13.1% | |||
| Orbimed Capital GP VI LLC | 9.6% | |||
| OrbiMed Genesis GP LLC | 3.6% | |||
| Orbimed Capital LLC | 1.2% | |||
|
Biotechnology Value Fund L P
13G/A
|
8.3% |
2/14/2025
Event 12/31/2024
|
||
| Biotechnology Value Fund L P | 4.3% | |||
| BVF I GP LLC | 4.3% | |||
| Biotechnology Value Fund II LP | 3.5% | |||
| BVF II GP LLC | 3.5% | |||
| Biotechnology Value Trading Fund OS LP | 0.4% | |||
| BVF Partners OS Ltd. | 0.4% | |||
| BVF GP Holdings LLC | 7.7% | |||
| BVF Partners L P/IL | 8.3% | |||
| BVF Inc/IL | 8.3% | |||
| Lampert Mark N | 8.3% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (3) | ||||
|
BML Investment Partners, L.P.
13D
|
8.5% |
6/16/2025
Event 6/16/2025
|
||
| BML Investment Partners, L.P. | 8.4% | |||
| Leonard Braden Michael | 8.5% | |||
| Gilead Sciences, Inc. 13G/A | 3.6% |
2/13/2025
Event 12/31/2024
|
||
|
Deep Track Capital, LP
13G/A
|
0% |
8/4/2025
Event 7/28/2025
|
||
| Deep Track Capital, LP | 0% | |||
| Deep Track Biotechnology Master Fund, Ltd. | 0% | |||
| David Kroin | 0% | |||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2025 Q2 | 43 | 31.8 M | $42.6 M |
| 2025 Q1 | 47 | 32.7 M | $41.9 M |
| 2024 Q4 | 54 | 31.7 M | $52.0 M |
| 2024 Q3 | 59 | 28.4 M | $49.1 M |
| 2024 Q2 | 73 | 29.1 M | $47.9 M |
| 2024 Q1 | 61 | 30.2 M | $42.9 M |
| 2023 Q4 | 58 | 32.5 M | $64.0 M |
| 2023 Q3 | 59 | 32.7 M | $142 M |
| 2023 Q2 | 53 | 31.2 M | $205 M |
| 2023 Q1 | 40 | 25.0 M | $86.2 M |
| 2022 Q4 | 36 | 26.3 M | $70.0 M |
| 2022 Q3 | 44 | 27.5 M | $97.8 M |
| 2022 Q2 | 47 | 26.8 M | $119 M |
| 2022 Q1 | 50 | 27.5 M | $168 M |
| 2021 Q4 | 51 | 27.4 M | $344 M |
| 2021 Q3 | 40 | 20.9 M | $272 M |
| 2021 Q2 | 43 | 21.1 M | $293 M |
| 2021 Q1 | 28 | 19.3 M | $539 M |